Current issue
Archive
Manuscripts accepted
About the Journal
Editorial office
Editorial board
Section Editors
Abstracting and indexing
Subscription
Contact
Ethical standards and procedures
Most read articles
Instructions for authors
Article Processing Charge (APC)
Regulations of paying article processing charge (APC)
SEXUOLOGY / STATE OF THE ART PAPER
Headaches, hormones, and transgender population: current evidence and knowledge gaps.
1
Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Poland
2
Doctoral School, Medical University of Warsaw, Poland
3
Department of Neurology, Medical University of Lublin, Poland
4
Department of Otorhinolaryngology and Oncological Laryngology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, Poland
5
Department of Pharmacokinetics and Therapeutic Drug Monitoring, Pomeranian Medical University, Poland
6
Department of Psychiatry, Bielanski Hospital, Poland
Submission date: 2026-04-10
Final revision date: 2026-05-03
Acceptance date: 2026-06-18
Online publication date: 2026-09-05
Corresponding author
Olga Grodzka
Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Cegłowska, 01-809, Warsaw, Poland
Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Cegłowska, 01-809, Warsaw, Poland
KEYWORDS
migrainetransgender individualsgender diverse individualsgender diverse populationprimary headache disorders
TOPICS
ABSTRACT
Migraine is a prevalent primary headache disorder affecting 14–17% of the global population and is strongly influenced by sex hormones. However, its characteristics in transgender individuals remain poorly understood and insufficiently studied. This review synthesizes evidence from 126 publications across neurology, otorhinolaryngology, pharmacology, and psychiatry to explore potential relationships between migraine and transgender health. Findings suggest that sex-related differences in migraine extend beyond epidemiology to clinical presentation, severity, and management, and may manifest uniquely in transgender patients. Factors such as gender-affirming hormone therapy, psychosocial stress, internal conflict, minority stress, and societal stigma may contribute to an increased headache burden. Additionally, barriers to healthcare access and limited provider knowledge may further complicate diagnosis and treatment. Despite these insights, data remain limited and fragmented. Greater awareness, interdisciplinary collaboration, and further research are needed to improve understanding and to develop more personalized, inclusive, and effective approaches to migraine management in transgender populations.
REFERENCES (140)
1.
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
2.
Stovner LJ, Hagen K, Linde M, Steiner TJ. The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain. 2022;23(1):34.
3.
Agosti R. Migraine Burden of Disease: From the Patient's Experience to a Socio-Economic View. Headache. 2018;58 Suppl 1:17-32.
4.
Drescher J, Cohen-Kettenis P, Winter S. Minding the body: situating gender identity diagnoses in the ICD-11. Int Rev Psychiatry. 2012;24(6):568-77.
5.
Cohen-Kettenis PT, Pfäfflin F. The DSM diagnostic criteria for gender identity disorder in adolescents and adults. Arch Sex Behav. 2010;39(2):499-513.
6.
Poteat T, Davis AM, Gonzalez A. Standards of Care for Transgender and Gender Diverse People. Jama. 2023;329(21):1872-4.
7.
Coleman E, Radix AE, Bouman WP, Brown GR, de Vries ALC, Deutsch MB, et al. Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. Int J Transgend Health. 2022;23(Suppl 1):S1-s259.
8.
Balthazart J. Minireview: Hormones and human sexual orientation. Endocrinology. 2011;152(8):2937-47.
9.
Bailey JM, Vasey PL, Diamond LM, Breedlove SM, Vilain E, Epprecht M. Sexual orientation, controversy, and science. Psychological science in the public interest. 2016;17(2):45-101.
10.
Fisher AD, Ristori J, Morelli G, Maggi M. The molecular mechanisms of sexual orientation and gender identity. Molecular and cellular endocrinology. 2018;467:3-13.
11.
Hranilovich JA, Kaiser EA, Pace A, Barber M, Ziplow J. Headache in transgender and gender-diverse patients: A narrative review. Headache. 2021;61(7):1040-50.
12.
Winter S, Diamond M, Green J, Karasic D, Reed T, Whittle S, Wylie K. Transgender people: health at the margins of society. Lancet. 2016;388(10042):390-400.
13.
Pace A, Barber M, Ziplow J, Hranilovich JA, Kaiser EA. Gender Minority Stress, Psychiatric Comorbidities, and the Experience of Migraine in Transgender and Gender-Diverse Individuals: a Narrative Review. Curr Pain Headache Rep. 2021;25(12):82.
14.
Godley F, 3rd, Meitzen J, Nahman-Averbuch H, O'Neal MA, Yeomans D, Santoro N, et al. How Sex Hormones Affect Migraine: An Interdisciplinary Preclinical Research Panel Review. J Pers Med. 2024;14(2).
15.
Gulati M, Dursun E, Vincent K, Watt FE. The influence of sex hormones on musculoskeletal pain and osteoarthritis. Lancet Rheumatol. 2023;5(4):e225-e38.
16.
Fitzek MP, Boucherie DM, de Vries T, Handtmann C, Fathi H, Raffaelli B, MaassenVanDenBrink A. Migraine in men. J Headache Pain. 2025;26(1):3.
17.
van Lohuizen R, Paungarttner J, Lampl C, MaassenVanDenBrink A, Al-Hassany L. Considerations for hormonal therapy in migraine patients: a critical review of current practice. Expert Rev Neurother. 2023;24(1):1-21.
18.
Spooner MF, Robichaud P, Carrier JC, Marchand S. Endogenous pain modulation during the formalin test in estrogen receptor beta knockout mice. Neuroscience. 2007;150(3):675-80.
19.
Athnaiel O, Cantillo S, Paredes S, Knezevic NN. The Role of Sex Hormones in Pain-Related Conditions. Int J Mol Sci. 2023;24(3).
20.
Reddy N, Desai MN, Schoenbrunner A, Schneeberger S, Janis JE. The complex relationship between estrogen and migraines: a scoping review. Syst Rev. 2021;10(1):72.
21.
MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. Neurology. 2006;67(12):2154-8.
22.
Raffaelli B, Storch E, Overeem LH, Terhart M, Fitzek MP, Lange KS, Reuter U. Sex Hormones and Calcitonin Gene-Related Peptide in Women With Migraine: A Cross-sectional, Matched Cohort Study. Neurology. 2023;100(17):e1825-e35.
23.
Kudo C, Harriott AM, Moskowitz MA, Waeber C, Ayata C. Estrogen modulation of cortical spreading depression. J Headache Pain. 2023;24(1):62.
24.
Stincic TL, Grachev P, Bosch MA, Rønnekleiv OK, Kelly MJ. Estradiol Drives the Anorexigenic Activity of Proopiomelanocortin Neurons in Female Mice. eNeuro. 2018;5(4).
25.
Lacroix-Fralish ML, Tawfik VL, Nutile-McMenemy N, DeLeo JA. Progesterone mediates gonadal hormone differences in tactile and thermal hypersensitivity following L5 nerve root ligation in female rats. Neuroscience. 2006;138(2):601-8.
26.
Kim MJ, Shin HJ, Won KA, Yang KY, Ju JS, Park YY, et al. Progesterone produces antinociceptive and neuroprotective effects in rats with microinjected lysophosphatidic acid in the trigeminal nerve root. Mol Pain. 2012;8:16.
27.
Carvalho B, Granot M, Sultan P, Wilson H, Landau R. A Longitudinal Study to Evaluate Pregnancy-Induced Endogenous Analgesia and Pain Modulation. Reg Anesth Pain Med. 2016;41(2):175-80.
28.
Chuang SH, Reddy DS. 3β-Methyl-Neurosteroid Analogs Are Preferential Positive Allosteric Modulators and Direct Activators of Extrasynaptic δ-Subunit γ-Aminobutyric Acid Type A Receptors in the Hippocampus Dentate Gyrus Subfield. J Pharmacol Exp Ther. 2018;365(3):583-601.
29.
Vincent K, Stagg CJ, Warnaby CE, Moore J, Kennedy S, Tracey I. "Luteal Analgesia": Progesterone Dissociates Pain Intensity and Unpleasantness by Influencing Emotion Regulation Networks. Front Endocrinol (Lausanne). 2018;9:413.
30.
Krause DN, Warfvinge K, Haanes KA, Edvinsson L. Hormonal influences in migraine - interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol. 2021;17(10):621-33.
31.
Hornung RS, Benton WL, Tongkhuya S, Uphouse L, Kramer PR, Averitt DL. Progesterone and Allopregnanolone Rapidly Attenuate Estrogen-Associated Mechanical Allodynia in Rats with Persistent Temporomandibular Joint Inflammation. Front Integr Neurosci. 2020;14:26.
32.
Gupta S, McCarson KE, Welch KM, Berman NE. Mechanisms of pain modulation by sex hormones in migraine. Headache. 2011;51(6):905-22.
33.
Al-Hassany L, van Drie RWA, Boucherie DM, MaassenVanDenBrink A. Unraveling the paradox: cardiovascular risk profiling in migraine- a correspondence. J Headache Pain. 2025;26(1):113.
34.
Somerville BW. The influence of progesterone and estradiol upon migraine. Headache. 1972;12(3):93-102.
35.
Aloisi AM, Ceccarelli I, Fiorenzani P. Gonadectomy affects hormonal and behavioral responses to repetitive nociceptive stimulation in male rats. Ann N Y Acad Sci. 2003;1007:232-7.
36.
Ceccarelli I, Scaramuzzino A, Massafra C, Aloisi AM. The behavioral and neuronal effects induced by repetitive nociceptive stimulation are affected by gonadal hormones in male rats. Pain. 2003;104(1-2):35-47.
37.
Lashkari M, Noori A, Oveisi S, Kheirkhah M. Association of serum testosterone and dehydroepiandrosterone sulfate with rheumatoid arthritis: a case control study. Electron Physician. 2018;10(3):6500-5.
38.
Pikwer M, Giwercman A, Bergström U, Nilsson J, Jacobsson LT, Turesson C. Association between testosterone levels and risk of future rheumatoid arthritis in men: a population-based case-control study. Ann Rheum Dis. 2014;73(3):573-9.
39.
White HD, Brown LA, Gyurik RJ, Manganiello PD, Robinson TD, Hallock LS, et al. Treatment of pain in fibromyalgia patients with testosterone gel: Pharmacokinetics and clinical response. Int Immunopharmacol. 2015;27(2):249-56.
40.
Verhagen IE, Brandt RB, Kruitbosch CMA, MaassenVanDenBrink A, Fronczek R, Terwindt GM. Clinical symptoms of androgen deficiency in men with migraine or cluster headache: a cross-sectional cohort study. J Headache Pain. 2021;22(1):125.
41.
Mattsson P. Serum levels of androgens and migraine in postmenopausal women. Clin Sci (Lond). 2002;103(5):487-91.
42.
Kobus M, Sitek A, Antoszewski B, Rożniecki J, Pełka J, Żądzińska E. Prenatal oestrogen-testosterone balance as a risk factor of migraine in adults. J Headache Pain. 2021;22(1):119.
43.
Glaser R, Dimitrakakis C, Trimble N, Martin V. Testosterone pellet implants and migraine headaches: a pilot study. Maturitas. 2012;71(4):385-8.
44.
Shields LBE, Seifert T, Shelton BJ, Plato BM. Testosterone levels in men with chronic migraine. Neurol Int. 2019;11(2):8079.
45.
Li W, Diao X, Chen C, Li C, Zhang Y, Li Y. Changes in hormones of the hypothalamic-pituitary-gonadal axis in migraine patients. J Clin Neurosci. 2018;50:165-71.
46.
van Oosterhout WPJ, Schoonman GG, van Zwet EW, Dekkers OM, Terwindt GM, MaassenVanDenBrink A, Ferrari MD. Female sex hormones in men with migraine. Neurology. 2018;91(4):e374-e81.
47.
Dourson AJ, Darken RS, Baranski TJ, Gereau RW, Ross WT, Nahman-Averbuch H. The role of androgens in migraine pathophysiology. Neurobiol Pain. 2024;16:100171.
48.
Avona A, Mason BN, Burgos-Vega C, Hovhannisyan AH, Belugin SN, Mecklenburg J, et al. Meningeal CGRP-Prolactin Interaction Evokes Female-Specific Migraine Behavior. Ann Neurol. 2021;89(6):1129-44.
49.
Parashar R, Bhalla P, Rai NK, Pakhare A, Babbar R. Migraine: is it related to hormonal disturbances or stress? Int J Womens Health. 2014;6:921-5.
50.
Guldiken S, Guldiken B, Demir M, Kabayel L, Ozkan H, Turgut N, et al. Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. J Headache Pain. 2011;12(3):355-60.
51.
Masoud SA, Fakharian E. Serum prolactin and migraine. Ann Saudi Med. 2005;25(6):489-91.
52.
Alia S, Ali RS, Nafiseh E, Ehsan K. Comparison the serum level of prolactin among patients with chronic and episodic migraine. Journal of Neurology Research. 2013;3(2):68-72.
53.
Hartman N, Voron SC, Hershman JM. Resolution of migraine following bromocriptine treatment of a prolactinoma (pituitary microadenoma). Headache. 1995;35(7):430-1.
54.
Cavestro C, Rosatello A, Marino MP, Micca G, Asteggiano G. High prolactin levels as a worsening factor for migraine. J Headache Pain. 2006;7(2):83-9.
55.
Maddahi A, Edvinsson L, Warfvinge K. Expression of vasopressin and its receptors in migraine-related regions in CNS and the trigeminal system: influence of sex. J Headache Pain. 2022;23(1):152.
56.
Buschmann J, Leppla-Wollsiffer G, Nemeth N, Nelson K, Kirsten R. Migraine patients show increased platelet vasopressin receptors. Headache. 1996;36(10):586-8.
57.
Bahadoram M, Mahmoudian-Sani M-R, Keikhaei B, Alikhani K, Bahadoram S. The antimigraine action of arginine-vasopressin: a theoretical basis. Taylor & Francis; 2020. p. FNL51.
58.
Tzabazis A, Kori S, Mechanic J, Miller J, Pascual C, Manering N, et al. Oxytocin and Migraine Headache. Headache. 2017;57 Suppl 2:64-75.
59.
Szewczyk AK, Ulutas S, Aktürk T, Al-Hassany L, Börner C, Cernigliaro F, et al. Prolactin and oxytocin: potential targets for migraine treatment. J Headache Pain. 2023;24(1):31.
60.
Phillips WJ, Ostrovsky O, Galli RL, Dickey S. Relief of acute migraine headache with intravenous oxytocin: report of two cases. J Pain Palliat Care Pharmacother. 2006;20(3):25-8.
61.
Wang YL, Yuan Y, Yang J, Wang CH, Pan YJ, Lu L, et al. The interaction between the oxytocin and pain modulation in headache patients. Neuropeptides. 2013;47(2):93-7.
62.
Warfvinge K, Krause DN, Maddahi A, Grell AS, Edvinsson JC, Haanes KA, Edvinsson L. Oxytocin as a regulatory neuropeptide in the trigeminovascular system: Localization, expression and function of oxytocin and oxytocin receptors. Cephalalgia. 2020;40(12):1283-95.
63.
Özge A, Peres MFP, Burstein R. Pediatric migraine care: bridging gaps, overcoming barriers, and advancing solutions. Eur J Pediatr. 2025;184(6):362.
64.
Lu G, Xiao S, Wang Y, Jia Q, Liu S, Yu S, et al. Global epidemiology and burden of headache disorders in children and adolescents from 1990 to 2021. Headache. 2025.
65.
Fonseca E, Torres-Ferrús M, Gallardo VJ, Macaya A, Pozo-Rosich P. Impact of Puberty in Pediatric Migraine: A Pilot Prospective Study. J Clin Neurol. 2020;16(3):416-22.
66.
Eidlitz-Markus T, Zeharia A. Symptoms and clinical parameters of pediatric and adolescent migraine, by gender - a retrospective cohort study. J Headache Pain. 2017;18(1):80.
67.
Maleki N, Bernstein C, Napadow V, Field A. Migraine and Puberty: Potential Susceptible Brain Sites. Semin Pediatr Neurol. 2016;23(1):53-9.
68.
Khan A, Liu S, Tao F. Current Trends in Pediatric Migraine: Clinical Insights and Therapeutic Strategies. Brain Sci. 2025;15(3).
69.
Maleki N, Kurth T, Field AE. Age at menarche and risk of developing migraine or non-migraine headaches by young adulthood: A prospective cohort study. Cephalalgia. 2017;37(13):1257-63.
70.
Greene K, Irwin SL, Gelfand AA. Pediatric Migraine: An Update. Neurol Clin. 2019;37(4):815-33.
71.
Martinez CI, Liktor-Busa E, Largent-Milnes TM. Molecular mechanisms of hormones implicated in migraine and the translational implication for transgender patients. Front Pain Res (Lausanne). 2023;4:1117842.
72.
Peterlin BL, Gupta S, Ward TN, Macgregor A. Sex matters: evaluating sex and gender in migraine and headache research. Headache. 2011;51(6):839-42.
73.
Al-Hassany L, Haas J, Piccininni M, Kurth T, Maassen Van Den Brink A, Rohmann JL. Giving Researchers a Headache - Sex and Gender Differences in Migraine. Front Neurol. 2020;11:549038.
74.
Allena M, De Icco R, Sances G, Ahmad L, Putortì A, Pucci E, et al. Gender Differences in the Clinical Presentation of Cluster Headache: A Role for Sexual Hormones? Front Neurol. 2019;10:1220.
75.
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17(11):954-76.
76.
Simmasalam R, Zuniga MC, Hinson HE. Neurological Health in Sexual and Gender Minority Individuals. Semin Neurol. 2024;44(2):193-204.
77.
Heslin KC. Explaining Disparities in Severe Headache and Migraine Among Sexual Minority Adults in the United States, 2013-2018. J Nerv Ment Dis. 2020;208(11):876-83.
78.
Lane IA, Zempsky WT. Capturing the experiences of sexual and gender minorities with migraine headache. Headache. 2023;63(7):971-4.
79.
Eitel KB, Hodax JK. Evaluation and medical care of intersex and gender diverse youth. Pediatr Radiol. 2024;54(8):1352-62.
80.
Nagata JM, Ganson KT, Tabler J, Blashill AJ, Murray SB. Disparities Across Sexual Orientation in Migraine Among US Adults. JAMA Neurol. 2020;78(1):117-8.
81.
Rosendale N, Guterman EL, Obedin-Maliver J, Flentje A, Capriotti MR, Lubensky ME, Lunn MR. Migraine, Migraine Disability, Trauma, and Discrimination in Sexual and Gender Minority Individuals. Neurology. 2022;99(14):e1549-e59.
82.
Volpe SG, Ahmad J, Patel RA, Rosendale N. Neurological care for LGBT+ people. Nat Rev Neurol. 2024;20(5):288-97.
83.
Nilles C, Williams JVA, Patten S, Pringsheim T, Orr SL. Association Between Peer Victimization, Gender Diversity, Mental Health, and Recurrent Headaches in Adolescents: A Canadian Population-Based Study. Neurology. 2023;101(17):e1654-e64.
84.
Savic I, Garcia-Falgueras A, Swaab DF. Sexual differentiation of the human brain in relation to gender identity and sexual orientation. Progress in brain research. 2010;186:41-62.
85.
Hines M, Constantinescu M, Spencer D. Early androgen exposure and human gender development. Biology of sex differences. 2015;6(1):3.
86.
Roselli CE. Neurobiology of gender identity and sexual orientation. Journal of neuroendocrinology. 2018;30(7):e12562.
87.
Zhou JN, Hofman MA, Gooren LJ, Swaab DF. A sex difference in the human brain and its relation to transsexuality. Nature. 1995;378(6552):68-70.
88.
Garcia-Falgueras A, Swaab DF. A sex difference in the hypothalamic uncinate nucleus: relationship to gender identity. Brain. 2008;131(Pt 12):3132-46.
89.
Simon L, Kozák LR, Simon V, Czobor P, Unoka Z, Szabó Á, Csukly G. Regional grey matter structure differences between transsexuals and healthy controls--a voxel based morphometry study. PLoS One. 2013;8(12):e83947.
90.
Hoekzema E, Schagen SE, Kreukels BP, Veltman DJ, Cohen-Kettenis PT, Delemarre-van de Waal H, Bakker J. Regional volumes and spatial volumetric distribution of gray matter in the gender dysphoric brain. Psychoneuroendocrinology. 2015;55:59-71.
91.
Kranz GS, Hahn A, Kaufmann U, Küblböck M, Hummer A, Ganger S, et al. White matter microstructure in transsexuals and controls investigated by diffusion tensor imaging. J Neurosci. 2014;34(46):15466-75.
92.
Taziaux M, Staphorsius AS, Ghatei MA, Bloom SR, Swaab DF, Bakker J. Kisspeptin Expression in the Human Infundibular Nucleus in Relation to Sex, Gender Identity, and Sexual Orientation. J Clin Endocrinol Metab. 2016;101(6):2380-9.
93.
Taziaux M, Swaab DF, Bakker J. Sex differences in the neurokinin B system in the human infundibular nucleus. J Clin Endocrinol Metab. 2012;97(12):E2210-20.
94.
Burke SM, Kreukels BP, Cohen-Kettenis PT, Veltman DJ, Klink DT, Bakker J. Male-typical visuospatial functioning in gynephilic girls with gender dysphoria - organizational and activational effects of testosterone. J Psychiatry Neurosci. 2016;41(6):395-404.
95.
Berglund H, Lindström P, Dhejne-Helmy C, Savic I. Male-to-female transsexuals show sex-atypical hypothalamus activation when smelling odorous steroids. Cereb Cortex. 2008;18(8):1900-8.
96.
Yalinay Dikmen P, Ertas M, Kosak S, Cimentepe C, Kocoglu M, Oztosun G, et al. Primary headaches among gender dysphoric female-to-male individuals: A cross-sectional survey on gender transition experience. Headache. 2021;61(8):1194-206.
97.
White Hughto JM, Reisner SL, Pachankis JE. Transgender stigma and health: A critical review of stigma determinants, mechanisms, and interventions. Soc Sci Med. 2015;147:222-31.
98.
Badaeva A, Maiolino L, Danilov A, Naprienko M, Danilov A, Jacob UM, Calabrese V. Neurogasobiology of migraine: Carbon monoxide, hydrogen sulfide, and nitric oxide as emerging pathophysiological trinacrium relevant to nociception regulation. Open Med (Wars). 2025;20(1):20251201.
99.
Hoskin KL, Bulmer DC, Goadsby PJ. Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci Lett. 1999;266(3):173-6.
100.
Valenti S, Fazzuoli L, Giusti M. Circulating nitric oxide levels increase after anti-androgen treatment in male-to-female transsexuals. J Endocrinol Invest. 2003;26(6):522-6.
101.
Pringsheim T, Gooren L. Migraine prevalence in male to female transsexuals on hormone therapy. Neurology. 2004;63(3):593-4.
102.
Aloisi AM, Bachiocco V, Costantino A, Stefani R, Ceccarelli I, Bertaccini A, Meriggiola MC. Cross-sex hormone administration changes pain in transsexual women and men. Pain. 2007;132 Suppl 1:S60-s7.
103.
MacGregor EA. Oestrogen and attacks of migraine with and without aura. Lancet Neurol. 2004;3(6):354-61.
104.
Ahmad SR, Rosendale N. Sex and Gender Considerations in Episodic Migraine. Curr Pain Headache Rep. 2022;26(7):505-16.
105.
Todd CM, Yu A, Lay C, Lagman-Bartolome AM. Effect of testosterone therapy on migraine frequency and disability in two transgender patients: a case report. BMJ Case Rep. 2023;16(1).
106.
Trovão Diniz E, Rocha Leite JB, Ribeiro Coutinho Madruga C, Maia Arca V, Macedo Cavalcanti Albuquerque JA, Sampaio Rocha-Filho PA. Headache in transgender men using gender-affirming hormone therapy: A case-control study. Headache. 2025.
107.
Hranilovich JA, Millington K. Headache prevalence in transgender and gender diverse youth: A single-center case-control study. Headache. 2023;63(4):517-22.
108.
Peper JS, Brouwer RM, Schnack HG, van Baal GC, van Leeuwen M, van den Berg SM, et al. Sex steroids and brain structure in pubertal boys and girls. Psychoneuroendocrinology. 2009;34(3):332-42.
109.
Koolschijn PC, Peper JS, Crone EA. The influence of sex steroids on structural brain maturation in adolescence. PLoS One. 2014;9(1):e83929.
110.
Roberts CM, Klein DA, Adirim TA, Schvey NA, Hisle-Gorman E. Continuation of Gender-affirming Hormones Among Transgender Adolescents and Adults. J Clin Endocrinol Metab. 2022;107(9):e3937-e43.
111.
Bockting WO, Miner MH, Swinburne Romine RE, Hamilton A, Coleman E. Stigma, mental health, and resilience in an online sample of the US transgender population. Am J Public Health. 2013;103(5):943-51.
112.
Holroyd KA, Stensland M, Lipchik GL, Hill KR, O'Donnell FS, Cordingley G. Psychosocial correlates and impact of chronic tension-type headaches. Headache. 2000;40(1):3-16.
113.
Steiner J. Psychic retreats: Pathological organizations in psychotic, neurotic and borderline patients: Routledge; 2003.
114.
Tabernacki T, Gilbert D, Rhodes S, Scarberry K, Pope R, McNamara M, et al. The burden of chronic pain in transgender and gender diverse populations: Evidence from a large US clinical database. Eur J Pain. 2025;29(2):e4725.
115.
Fillingim RB, King CD, Ribeiro-Dasilva MC, Rahim-Williams B, Riley JL, 3rd. Sex, gender, and pain: a review of recent clinical and experimental findings. J Pain. 2009;10(5):447-85.
116.
Tsang A, Von Korff M, Lee S, Alonso J, Karam E, Angermeyer MC, et al. Common chronic pain conditions in developed and developing countries: gender and age differences and comorbidity with depression-anxiety disorders. J Pain. 2008;9(10):883-91.
117.
Bimpong K, Thomson K, McNamara CL, Balaj M, Akhter N, Bambra C, Todd A. The Gender Pain Gap: gender inequalities in pain across 19 European countries. Scand J Public Health. 2022;50(2):287-94.
119.
Martin V, Wernke S, Mandell K, Zoma W, Bean J, Pinney S, et al. Medical oophorectomy with and without estrogen add-back therapy in the prevention of migraine headache. Headache. 2003;43(4):309-21.
121.
Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. Lancet Neurol. 2017;16(1):76-87.
122.
Epstein MT, Hockaday JM, Hockaday TD. Migraine and reporoductive hormones throughout the menstrual cycle. Lancet. 1975;1(7906):543-8.
123.
Vincent K, Warnaby C, Stagg CJ, Moore J, Kennedy S, Tracey I. Brain imaging reveals that engagement of descending inhibitory pain pathways in healthy women in a low endogenous estradiol state varies with testosterone. Pain. 2013;154(4):515-24.
124.
Moehlig RC. Methyl testosterone for migraine of women; report of sixty cases. J Mich State Med Soc. 1955;54(5):577-9; passim.
125.
Keogh E. Sex and gender differences in pain: past, present, and future. Pain. 2022;163(Suppl 1):S108-s16.
126.
Craft RM, Mogil JS, Aloisi AM. Sex differences in pain and analgesia: the role of gonadal hormones. Eur J Pain. 2004;8(5):397-411.
127.
Institute of Medicine Committee on Lesbian GB, Transgender Health I, Research G, Opportunities. The National Academies Collection: Reports funded by National Institutes of Health. The Health of Lesbian, Gay, Bisexual, and Transgender People: Building a Foundation for Better Understanding. Washington (DC): National Academies Press (US).
129.
Ólason M, Andrason RH, Jónsdóttir IH, Kristbergsdóttir H, Jensen MP. Cognitive Behavioral Therapy for Depression and Anxiety in an Interdisciplinary Rehabilitation Program for Chronic Pain: a Randomized Controlled Trial with a 3-Year Follow-up. Int J Behav Med. 2018;25(1):55-66.
130.
Verma S, Gallagher RM. The psychopharmacologic treatment of depression and anxiety in the context of chronic pain. Curr Pain Headache Rep. 2002;6(1):30-9.
131.
Songer D. Psychotherapeutic approaches in the treatment of pain. Psychiatry (Edgmont). 2005;2(5):19-24.
132.
Hajek A, König HH, Buczak-Stec E, Blessmann M, Grupp K. Prevalence and Determinants of Depressive and Anxiety Symptoms among Transgender People: Results of a Survey. Healthcare (Basel). 2023;11(5).
133.
De La Rosa JS, Brady BR, Ibrahim MM, Herder KE, Wallace JS, Padilla AR, Vanderah TW. Co-occurrence of chronic pain and anxiety/depression symptoms in U.S. adults: prevalence, functional impacts, and opportunities. Pain. 2024;165(3):666-73.
134.
Martinez CI, Liktor-Busa E, Largent-Milnes TM. Problems in management of medication overuse headache in transgender and gender non-conforming populations. Front Neurol. 2024;15:1320791.
135.
Weitzer D. How to provide effective pain management to LGBTQ individuals. Pract Pain Manag. 2019;19(6).
136.
Tordoff DM, Wanta JW, Collin A, Stepney C, Inwards-Breland DJ, Ahrens K. Mental health outcomes in transgender and nonbinary youths receiving gender-affirming care. JAMA network open. 2022;5(2):e220978-e.
137.
Hughto JM, Restar AJ, Wolfe HL, Gordon LK, Reisner SL, Biello KB, et al. Opioid pain medication misuse, concomitant substance misuse, and the unmet behavioral health treatment needs of transgender and gender diverse adults. Drug and alcohol dependence. 2021;222:108674.
138.
Gordon AR, Krieger N, Okechukwu CA, Haneuse S, Samnaliev M, Charlton BM, Austin SB. Decrements in health-related quality of life associated with gender nonconformity among U.S. adolescents and young adults. Qual Life Res. 2017;26(8):2129-38.
139.
Abd-Elsayed A, Heyer AM, Schatman ME. Disparities in the Treatment of the LGBTQ Population in Chronic Pain Management. J Pain Res. 2021;14:3623-5.
140.
Anger JT, Case LK, Baranowski AP, Berger A, Craft RM, Damitz LA, et al. Pain mechanisms in the transgender individual: a review. Front Pain Res (Lausanne). 2024;5:1241015.
Share
RELATED ARTICLE
| eISSN: | 1896-9151 |
| ISSN: | 1734-1922 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
